Regeneron Pharmaceuticals (REGN) stock is in focus after the company announced an expanded global alliance with long-term partner Sanofi (SNY). REGN said it will receive $1 billion in upfront cash and stands to earn up to $7 billion in milestone payments, driving the total potential value of the expanded contract to about $8 billion.
At the time of writing, Regeneron stock is down about 13% versus its recent high.